Drugs / Foxy-5
Foxy-5
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02655952 | Apr 2016 → Oct 2017 | breast cancer, malignant colon neoplasm, prostate cancer | WntResearch AB | Completed | No outcome recorded |
| Phase 1 | NCT02020291 | Jun 2013 → Nov 2015 | breast cancer, colorectal cancer, prostate cancer | WntResearch AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03883802 | Apr 2019 → Dec 2024 | colorectal cancer | WntResearch AB | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Foxy-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02020291 ↗ |
| Known as | N-formyl-met-asp-gly-cys-glu-leu | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297281 ↗ |
| Known as | Wnt-5a derived hexapeptide foxy-5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297281 ↗ |
| Modality | Peptide | “formylated 6 amino acid peptide fragment” NCT02020291 ↗ |
| Route | Other | “Slow infusion of lyophilised and reconstituted Foxy-5 three times weekly for three weeks.” NCT02655952 ↗ |